Management of Recurrent Shingles in a 67-Year-Old Male with Waldenström Macroglobulinemia
This patient requires antiviral prophylaxis with valacyclovir or acyclovir due to the profound immunosuppression from Waldenström macroglobulinemia and its treatment, which places him at high risk for recurrent varicella-zoster virus (VZV) reactivation.
Immediate Antiviral Management
The recurrent shingles episodes indicate significant immunocompromise from the underlying lymphoproliferative disorder. While the provided guidelines focus on WM treatment rather than infection prophylaxis specifically, the immunosuppressive nature of WM and its therapies creates substantial VZV reactivation risk 1.
Key prophylactic approach:
- Long-term suppressive antiviral therapy with valacyclovir 500 mg daily or acyclovir 400-800 mg twice daily
- Continue prophylaxis throughout active WM treatment and for at least 6-12 months after completing immunosuppressive therapy
- HSV and HZV prophylaxis is beneficial for patients requiring extensive WM treatment 1
Assessment of Underlying WM Disease Activity
The recurrent infections may signal:
Active disease requiring treatment - Evaluate for:
- Hemoglobin <10 g/dL
- Platelets <100 × 10⁹/L
- Bulky adenopathy or organomegaly
- Constitutional symptoms
- IgM-related complications (hyperviscosity, neuropathy, cryoglobulinemia)
If symptomatic WM is present, treatment options based on disease severity 2:
For Modest Disease Burden:
- Rituximab monotherapy (375 mg/m² weekly × 4 weeks) without maintenance 3
- Avoid rituximab maintenance as it increases infection risk without proven benefit in WM 2
For Severe/Bulky Disease:
- Bendamustine-rituximab (preferred first-line) 2
- Dexamethasone-rituximab-cyclophosphamide (DRC) as alternative, particularly for non-bulky disease 3
Critical Infection Prevention Measures
Comprehensive prophylaxis strategy 1:
- VZV prophylaxis: Valacyclovir or acyclovir (as above)
- Pneumocystis jiroveci prophylaxis: Trimethoprim-sulfamethoxazole (highly recommended during active treatment)
- Hepatitis B screening: Required before initiating therapy
- Vaccinations: SARS-CoV-2 and seasonal influenza vaccines (though response may be blunted)
Common Pitfalls to Avoid
Do not treat based on IgM levels alone - IgM elevation without symptoms is not an indication for therapy 1
Avoid purine nucleoside analogues (fludarabine, cladribine) in this patient:
Watch for rituximab IgM flare - Can cause paradoxical IgM increase for up to 4 months, potentially triggering hyperviscosity 3. Consider plasmapheresis if symptomatic.
Do not discontinue antiviral prophylaxis prematurely - Continue throughout immunosuppressive therapy and extended period after completion
Treatment Selection Algorithm
If WM is asymptomatic (preserved hemoglobin, no organomegaly, no constitutional symptoms):
- Observe without WM-directed therapy 3
- Initiate antiviral prophylaxis regardless
- Monitor every 3-6 months
If WM requires treatment:
- Start antiviral prophylaxis immediately
- Add PCP prophylaxis
- Choose WM therapy based on disease burden (bendamustine-rituximab for bulky disease, rituximab alone for modest disease)
- Continue prophylaxis throughout treatment and 6-12 months post-therapy
The recurrent shingles itself is a marker of immunocompromise that warrants aggressive prophylactic measures, regardless of whether the underlying WM currently requires treatment. The goal is preventing further VZV reactivations while addressing any active lymphoproliferative disease contributing to immune dysfunction.